Section Arrow
Quote
ALMS.NASDAQ
- Alumis Inc.
Quotes are at least 15-min delayed:2025/05/25 03:25 EDT
Last
 4.875
+0.035 (+0.72%)
Day High 
4.98 
Prev. Close
4.84 
1-M High
6.185 
Volume 
1.05M 
Bid
4.39
Ask
4.88
Day Low
4.6917 
Open
4.88 
1-M Low
3.79 
Market Cap 
263.32M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.07 
20-SMA 4.74 
50-SMA 5.35 
52-W High 13.53 
52-W Low 3.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.24/-3.44
Enterprise Value
292.49M
Balance Sheet
Book Value Per Share
3.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PLRZPolyrizon Ltd0.0034-0.0008-19.05%-- 
IMNNImunon1.16+0.7445+179.18%-- 
NCNANuCana plc0.038-0.0014-3.55%-- 
RXRXRecursion Pharmaceuticals4.08-0.065-1.57%-- 
KLTOKlotho Neurosciences Inc0.1923+0.0033+1.75%-- 
Quotes are at least 15-min delayed：2025/05/25 03:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.